{
  "thread": {
    "uuid": "91b6dd09a6ecd66750b74b0bee237a981268f0ce",
    "url": "https://finance.sina.com.cn/stock/aiassist/pzzd/2026-01-15/doc-inhhkmpv3320093.shtml",
    "site_full": "finance.sina.com.cn",
    "site": "sina.com.cn",
    "site_section": "https://finance.sina.cn/?from=redirect",
    "site_categories": [
      "tech",
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news",
      "politics",
      "science and technology",
      "economy, business and finance"
    ],
    "section_title": "新浪财经_金融信息服务商",
    "site_title": "æ°æµªè´¢ç»_éèä¿¡æ¯æå¡å",
    "title": "宣泰医药跌2.05%，成交额3456.14万元，主力资金净流出210.79万元|流通股东_新浪财经_新浪网",
    "title_full": "宣泰医药跌2.05%，成交额3456.14万元，主力资金净流出210.79万元|流通股东_新浪财经_新浪网",
    "published": "2026-01-15T08:11:00.000+02:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 548,
    "domain_rank_updated": "2026-01-11T23:00:00.000+02:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "91b6dd09a6ecd66750b74b0bee237a981268f0ce",
  "url": "https://finance.sina.com.cn/stock/aiassist/pzzd/2026-01-15/doc-inhhkmpv3320093.shtml",
  "ord_in_thread": 0,
  "author": "小浪财讯",
  "published": "2026-01-15T08:11:00.000+02:00",
  "title": "宣泰医药跌2.05%，成交额3456.14万元，主力资金净流出210.79万元|流通股东_新浪财经_新浪网",
  "text": "1月15日， 宣泰医药 盘中下跌2.05%，截至14:10，报10.51元/股，成交3456.14万元，换手率0.72%，总市值47.65亿元。\n资金流向方面，主力资金净流出210.79万元，大单买入415.05万元，占比12.01%，卖出625.84万元，占比18.11%。\n宣泰医药今年以来股价涨8.35%，近5个交易日涨3.85%，近20日涨7.24%，近60日跌2.50%。\n资料显示，上海宣泰医药科技股份有限公司位于上海市浦东新区海科路99号3号楼一楼，成立日期2012年8月13日，上市日期2022年8月25日，公司主营业务涉及仿制药的研发、生产和销售以及CRO服务。主营业务收入构成为：产品销售收入69.85%，CRO研发服务9.38%，权益分成收入6.50%，CMO加工服务6.31%，代理权收入3.93%，自研项目转让收入3.89%，其他(补充)0.12%。\n宣泰医药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：熊去氧胆酸、生物医药、仿制药、创新药、小盘等。\n截至9月30日，宣泰医药股东户数7759.00，较上期减少3.25%；人均流通股58427股，较上期增加229.25%。2025年1月-9月，宣泰医药实现营业收入3.31亿元，同比减少8.59%；归母净利润6346.25万元，同比减少31.45%。\n分红方面，宣泰医药A股上市后累计派现8558.57万元。\n机构持仓方面，截止2025年9月30日，宣泰医药十大流通股东中，香港中央结算有限公司位居第九大流通股东，持股186.74万股，为新进股东。中证上海国企ETF（510810）退出十大流通股东之列。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance"
  ],
  "topics": [
    "Economy, Business and Finance->financial and economic news",
    "Economy, Business and Finance->business and market analysis",
    "Economy, Business and Finance->market and exchange"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": true,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2026-01-15T08:16:27.819+02:00",
  "updated": "2026-01-16T09:07:44.000+02:00"
}